TC Biopharm (Holdings) Plc (TCBP)

USD 0.65

(38.59%)

Market Cap (In USD)

16.07 Thousand

Revenue (In USD)

-

Net Income (In USD)

-5.9 Million

Avg. Volume

198.9 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.436-41.5
PE
-
EPS
-
Beta Value
0.249
ISIN
US87807D4007
CUSIP
87807D103
CIK
1872812
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Bryan Leland Kobel
Employee Count
-
Website
https://www.tcbiopharm.com
Ipo Date
2022-02-11
Details
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.